🫁 Ventilator-Associated #Pneumonia (VAP) is the target of one of the 5 Perpetual Observational Studies (POS) in ECRAID-Base. But does it even exist? Read Marc Bonten's blog post on this fascinating question 👇🏾 Learn more about the POS-VAP study which has already enrolled more than 2000 patients 👉🏼 https://lnkd.in/eZDgWT97 UMC Utrecht, Centre d'Investigation Clinique du CHU de Limoges, European Respiratory Society, Ana Hernandez, European Commission #infectiousdiseases #clinicaltrials #clinicalresearch

Don't miss these #CME symposia coming to Kiawah Eye 2024 this weekend!   First up on Friday at 12:00 PM ET is "Visionary Solutions: Mastering nAMD & DME in the Modern Era." Carl Regillo, MD, FACS and Durga S. Borkar, MD, MMCi will assess real-world evidence to integrate therapeutic regimens into practice, ensuring the utmost care for patients dealing with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This activity is supported by an educational grant from Genentech, a member of the Roche Group. Then, on Saturday at 10:35 AM ET is "Eye Spy, TED in Disguise: Unmasking and Taming Thyroid Eye Disease." Andrea Kossler, MD, FACS and Jennifer Loh, MD will discuss risk factors and classification criteria that aid in the timely differential diagnosis of TED. They will also evaluate treatment strategies that have a favorable benefit-risk profile to improve outcomes and patient satisfaction. This activity is supported by educational funding provided by Amgen. For more information on Kiawah Eye 2024, visit this link: https://lnkd.in/eaAeTnzD

Members of the National MS Society’s Medical Committee, Dr. Bassem Yammout and Joelle Massouh will be presenting at this year’s ECTRIMS in Copenhagen.    Here is a glimpse into the topics they will be delving into.   Don’t miss out on their presentations! Please also pass by the poster presentations to learn about their recent research: Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience Poster Presentation Session 1 at the Paper Poster Area Wednesday, 18 September 2024, 16:15 - 18:15 CEST The Comparative Effectiveness of Natalizumab and Anti-CD20 Monoclonal Antibodies in Relapsing-Remitting Multiple Sclerosis: A Real-World based Study Free Communications 6: Treatment 2 Thursday, 19 September 2024, 15:30 - 15:40 CEST #MSSocietyUAE #MultipleSclerosis #MSawareness #LivingwithMS #MSCommunityUAE #MSResearch #ECTRIMS #ECTRIMS2024

As our eagerly anticipated conference approaches, with just under three weeks to go, we invite you to explore some of the exciting programme highlights and distinguished speakers we have lined up. Don’t miss the chance to attend, secure your place now and join us for a conference that promises to deliver exceptional content and connections. Book your spot today! ➡ Dr Alan Remaley (Bethesda, Maryland, USA) LDL-C calculation – What comes next after Friedewald? Describing recent advances in low-density lipoproteins and their diagnostic and therapeutic implications. ➡ Dr Jean-Luc Eiselé (Geneva, Switzerland) Plenary speaker Dyslipidemia and Cardiovascular Disease: A Global Perspective Implementable policies to increase awareness, diagnostic, access and adherence to treatments on a global scale. ➡ Prof Jeanine Roeters van Lennep (Rotterdam, The Netherlands) Empowering change: The EAS call to action on women, lipids and CVD It is essential to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women. ➡Prof Steve Humphries (London, UK)  Unlocking the Future; Familial Hypercholesterolaemia and the Newborn Genomes Programme What are the potential benefit and possible drawbacks of identifying families with FH by whole genome sequencing of a newborn baby? https://lnkd.in/eKGXK_vP #hukconf #lipids

This breakthrough technology will not only benefit those with kidney disease but also those of us with autoimmune diseases that cause our bodies to have chronic fluctuating potassium levels. The possibility of having a home device that can instantly test potassium levels rather than require a visit to the emergency room, and wait for hours while costs pile up, is incredible. For those with potassium fluctuations, the side affects of too low and too high are very similar resulting in constant personal deliberations over perceived daily potassium levels. Praying this technology comes to market and is affordable for everyone in need of such a life changing tool.

Episode 2 of Beyond the Chart with Dr. Dash is now live! 🎙 In this episode, Rajesh Dash MD PhD engages in an insightful conversation with Bethany Kalich, a clinical pharmacist and the U.S. Cardiovascular Medical Director at Amgen. Together, they explore the ambitious health goals set for 2030 and the collaborative efforts required to make significant strides in cardiovascular health. 🔎 Key Topics Covered: - Ambitious Health Goals for 2030: Cutting cardiovascular events in half by 2030 through system-wide collaboration across healthcare providers and pharmaceutical partners. - Increasing LDL Testing Rates: Doubling LDL cholesterol testing rates as a critical early milestone in improving cardiovascular health. - Implementation Science and Quality Measures: Advancing LDL testing and goal achievement through the Lattice consortium, focusing on quality measures for enhanced care. - Addressing Disparities in Healthcare: Ensuring equitable access to healthcare interventions for groups with higher cardiovascular disease burdens. Tune in to learn more about the role of technology, real-world evidence, and systemic collaboration in shaping the future of healthcare. 🎧 Listen now: https://lnkd.in/gfZQYNvV #cardiovascularhealth #cardiology #healthcareinnovation #medicaleducation #clinicalops #clinicaltrials #clinicalcare #clinicalintelligence #healthtech

The #SLEIMPN meeting is one of the largest conferences on metabolic diseases and neonatal screening in South America. This year it will be held in Punta del Este in Uruguay on 22-25 October, and members of the clinical team at AZAFAROS B.V. will be there to present the results of two clinical trials. Our #PRONTO study, a prospective natural history study of the disease progression of patients with late-infantile/juvenile onset #GM1 and #GM2 gangliosides, will be presented as a poster with an update on patient follow-up. Our #RAINBOW study, a Phase 2 trial carried out in Brazil to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and explore the efficacy of our lead asset, #nizubaglustat, will also be presented as a poster. #SLEIMPN2024 (XIII Congreso de la Sociedad Latinoamericana de Errores Innatos del Metabolismo y Pesquisa Neonatal), will be a great opportunity for the Azafaros team to impart knowledge of the natural history of GMx diseases, and to share our progress with nizubaglustat, a small molecule being investigated in lysosomal neurodegenerative diseases such as NPC, GM1, and GM2. At the same time, it is a fantastic opportunity to engage with and strengthen our bond with the Central and South American rare disease community. See you there! #Azafaros, #SLEIMPN, #conferencing, #collaboration, #rarediseases, #GM1, #GM2, #NPC, #clinicaltrials, #biotech

🟡 New article in DIA Read our article in this month's DIA magazine on the patient-focused approach we have taken to developing our diagnostic TPP document. We have incorporated crucial input from people with Cystic Fibrosis from the outset and throughout. Engaging people with lived experience early in TPP development provides invaluable insights into real-world experiences, unmet needs and preferences that can't be found in textbooks or databases. Read here: https://ow.ly/ccgT50Tj4eQ Medicines Discovery Catapult | Cystic Fibrosis Trust | LifeArc NIHR HRC in Diagnostic and Technology Evaluation #CysticFibrosis #AMR #TPP

Andrew Holden (Auckland, New Zealand), one of the co-chairs of the Charing Cross (CX) International Symposium, presented the final five-year data on the vital status of patients enrolled in the IN.PACT AV Access pivotal trial in April 2024 as a podium-first presentation. Due to the paclitaxel safety concerns raised, the researchers re-consented patients enrolled in the trial to prolong the follow-up period to establish their long-term vital status. “The all-cause mortality remains the same out to five years. There is no mortality concern using the IN.PACT [AV] drug-coated balloon (DCB). The long-term durability of this study really shows that the IN.PACT DCB should be the standard of care in maintaining [the] AV [arteriovenous] access circuit,” Holden said, reminding the audience that this is the only randomised, pivotal trial in AV access circuits to demonstrate a consistent and sustained clinical benefit out to three years. The IN.PACT AV Access randomised controlled trial comparing plain balloon angioplasty with DCB angioplasty in managing stenotic disease in AV access has previously shown significantly improved sustained benefits for end-stage kidney disease patients at the three-year time point. Further research has also demonstrated a cost-effectiveness advantage for healthcare systems in Japan, Korea and the USA, when the device is used. Watch now: https://lnkd.in/eCPBuqsW This video is sponsored by Medtronic. #dcb #avaccess #maintenance #ESKD #dialysis  

#Peripheral_Interventions Market Expansion Projected to Gain an Uptick During 2023-2032 https://lnkd.in/d2aZqGBb With an increase in the #geriatric population, the #burden of peripheral artery disease (PAD) is increasing. The growing #FDA approval for new treatments and #devices, awareness programme and advances in the market is estimated to #boost the growth. Medtronic Boston Scientific Boston Scientific en Costa Rica Abbott Terumo Medical Corporation Terumo Europe C. R. Bard GmbH